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ABSTRACT 
Dyslipidemia is a common finding in most studies ofliver diseases. Little is however known 
about the effect of the two pathological stages of chronic hepatitis B (CHB) infection – chronic-
symptomatic and asymptomatic – on the distribution f serum lipids in CHB infection. We con-
ducted a study on CHB-infected patients attending specialist care at the Gastro-Intestinal (GI) 
Clinic at the Komfo Anokye Teaching Hospital (KATH) during a 7-month period. 64 partici-
pants were randomly sampled over the period. On the basis of serological and liver enzyme as-
says, participants were categorised as chronic asympto atic, chronic symptomatic and healthy 
individuals. The relationship between the hosts pathological stage of infection were evaluated 
with the indices of lipid metabolism – LDL, HDL, triglyceride, and total serum cholesterol using 
ANOVA. The 64 volunteers recruited in the study were found to consist of 18 patients (28.1%) 
who were chronic symptomatic, 35 patients (54.7%) who were chronic asymptomatic hepatitis B, 
and 11 (17.2%) were healthy subjects. Significant overall male dominance was observed among 
all categories of population enrolled (p=0.0063). Serum triglyceride levels decreased more 
among the CHB-infected population compared to the halthy individuals (p=0.0010) with value 
lowest among the chronic symptomatic population. Basal serum cholesterol, HDL, and LDL 
were unaffected by the disease. This work reveals that serum triglyceride is significantly lowered 
in CHB infection and that the extent of this decrease in host is independent of the pathological 
stage of the infection.  
INTRODUCTION  
Hepatitis B virus (HBV) infection is a serious 
global health problem, with 2 billion people 
infected worldwide, and 350 million suffering 
from chronic HBV infection of which nearly 
500,000 – 1.2 million die annually due to 
chronic hepatitis, cirrhosis, and hepatocellular 
carcinoma, and other liver-related complica-
tions (WHO, 2000). Mortality due to liver dis-
eases ranks fifth worldwide even though it 
ranks higher in developing countries like Ghana 
where viral hepatitis infection (hepatitis B and 
or C) is very endemic with ≈ 15% with rate 
(Sarkodie et al., 2001).  
 
The nature and extent of association of chronic 
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 have been very diverse showing slight to 
marked variations in plasma lipoprotein and 
apolipoprotein patterns.  In one study of the 
dyslipidemia in chronic hepatitis, liver cirrhosis 
and hepato-cellular carcinoma, the TG and cho-
lesterol levels decreased while LDL–
cholesterol fraction increased with HDL-
fraction remaining fairly unchanged. Metastatic 
liver cancer however showed a lower serum 
HDL–fraction compared to hepato-cellular car-
cinoma where higher levels of HDL, total cho-
lesterol, and triglycerides were observed (Ooi 
et al., 2005). Su et al. (2004) reported a marked 
elevation of serum ALT as a correlate to lower 
levels of HDL-cholesterol (HDL-C) in patients 
with asymptomatic chronic hepatitis B, and 
also as a correlate to lower serum HDL-C and 
higher TG levels in patients without HBV in-
fection. Altogether, the increased LDL-C and 
the lower plasma HDL-C may pose increased 
cardiovascular risk to patients of liver disease.  
 
Most researchers report of slight to major in-
crease in serum levels of apolipoproteins and 
lipoproteins in patients suffering from various 
liver diseases (Su et al., 2004; Jiang et al., 
2008). In one recent study, Jiang et al, (2008) 
reported of decreased apolipoprotein-A1 
(ApoA1) and lipoprotein-a (Lp(a)) levels in 
patients suffering from hepatocellular carci-
noma. In the same study, they found very high 
levels of ApoM proteins among patients suffer-
ing from chronic hepatitis B, HCC, and liver 
cirrhosis. 
 
Pathophysiologically, there are two main stages 
of chronic hepatitis B infection – chronic symp-
tomatic (fulminant chronic hepatitis B infec-
tion) and chronic asymptomatic stage with their 
attendant pathological manifestations. How-
ever, most studies of dyslipidemia involving 
chronic hepatitis B infection have not investi-
gated the bearing of these stages on lipid profile 
of infected hosts. The aim of this study there-
fore was to assess the effect of these stages of 
chronic hepatitis B infection on distribution of 
plasma lipids. 
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hepatitis B disease and plasma metabolite dys-
regulation has become the subject of interest by 
most biomedical researchers over the past dec-
ade. The liver as a homeostatic organ plays a 
pivotal role in modulating endogenous and ex-
ogenous cycles of lipid metabolism. It is in-
volved in the sequestration, remodelling 
(synthesis or recycling), and redistribution of 
lipid metabolites including lipoproteins such as 
low-density lipoproteins (LDL), high-density 
lipoproteins (HDL), and their corresponding 
apolipoproteins - ApoB, and Apo A1, etc., 
triglycerides (TG), and total plasma cholesterol.  
Thus the extracellular circulating levels of these 
metabolites in plasma depend significantly on 
the functional integrity of the hepatic tissues. 
Mild to severe liver deranging factors such as 
chronic hepatitis B infection could potentially 
interfere directly or indirectly with the levels of
these lipid substrates in the plasma of infected 
hosts. Similarly, the chronic pro-inflammatory 
cytokine surge that characterise most cases of 
chronic hepatitis B could as well alter plasma 
lipid distribution. Such cytokines including 
tumor necrosis factor – alpha (TNF-α), inter-
feron – α (IFN-α) and IFN-γ, interleukin (IL)-1, 
IL-2, and IL-6 directly exert their influence on 
lipid metabolic pathways in the liver (Michiel 
and Oppenheim, 1992; Argiles et al., 1989; 
Kwong et al., 1997; Navasa et al., 1998).The 
effect of cytokines on serum lipid metabolism 
is often a direct one and not hormone-mediated 
which involves concerted signalling factors and 
intermediates. Most pro-inflammatory cyto-
kines generally increase lipogenesis, very low 
density lipoprotein (VLDL) production and 
consequently increase in circulating LDL levels 
in serum. On the other hand, they decrease he-
patic lipase activity in vitro (Feingold et al., 
1992; Feingold and Grunfeld, 1987; Feingold et 
al., 1989; Nonogaki et al., 1995). 
 
Dyslipidemia in liver diseases, as reported by 
most researchers, has been largely attributed to
the decrease in the biosynthetic and bioprocess-
ing capacity of the liver in diseased state as 
with chronic hepatitis B infection. Reports on 
the profile of lipids in cases of liver diseases 
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PATIENTS AND METHODS 
Subjects and Sample collection 
Between September 2009 and March 2010, 64 
volunteers were randomly recruited. Alto-
gether, they included 35 patients with asympto-
matic CHB (22 males and 13 females, median 
age: 30yrs, age range: 23 – 44yrs), 18 patients 
with symptomatic CHB (15 males and 3 fe-
males, median age: 35 years, age range: 23 – 47 
yrs), on admission or attending specialist care 
at the GI Clinic, Out-patient Department of the 
Komfo Anokye Teaching Hospital (KATH). 
Eleven apparently healthy individuals from the 
university campus (8 males and 3 females, me-
dian age: 26 years, age range: 23 – 29 years) 
who tested seronegative for the HBsAg and 
HBcAg were randomly recruited as negative 
controls. The study was approved by the Com-
mittee on Human Research, Ethics, and Publi-
cations, School of Medical Science, KNUST – 
Kumasi, and signed or thumb-printed informed 
consent was received from each volunteer prior 
to enrollment. 10 ml intravenous blood drawn 
from volunteers were allowed to clot in sterile 
non-heparinised blood tubes and centrifuged at 
3000 r/min for 10 minutes. The serum was col-




Except for healthy controls, all other volunteers 
were recruited on the basis that they had 
chronic hepatitis B infection and have lived 
with it for at least six months after certified 
clinical diagnosis and awareness. Healthy con-
trols had no clinical history of HBV-infection.  
 
Exclusion criteria 
Patients with records of alcoholism, smoking, 
or suggested dependence on herbal concoc-
tion in the week of the recruitment were not 
considered for the study. 
 
Cohorts that had clinical records of cocomi-
tant illnesses such as diabetes mellitus, hy-
pertension, and other endocrine disorders 
were all excluded  
 
Hepatitis virus markers and virologic studies  
HBsAg, antibody to HBsAg (anti-HBs), 
HBeAg, and anti-HBeAg were assayed with 
commercial kits (AxSYM System, Abbott 
Laboratories, North Chicago, IL).  
 
Serum transaminase assay 
Serum levels of alanine and aspartate transami-
nases (ALT and AST) were assayed by a semi-
automated approach using commercial For-
tress® test kits (Fortress Diagnostics Ltd., An-
trim BT41 1QS, UK) and Humalyzer Jnr. 
18050 chemistry analyzer (Human Diagnostica, 
Germany). Patients were grouped into two cate-
gories based on their serum AST and ALT lev-
els and HBV-serology namely: CHB-
asymptomatic (anti-HBcAg +ve, HBsAg +ve, 
and serum AST and ALT ≤ 40 IU/l) or CHB-
symptomatic (anti-HBcAg +ve, HBsAg +ve, 
serum AST and ALT ≥ 40 IU/l). Healthy indi-
viduals were anti-HBcAg -ve, HBsAg -ve, and 
had serum AST and ALT ≤ 40 IU/l. 
 
Serum lipid profile 
Total serum cholesterol, LDL-, HDL-
cholesterol (HDL-C), and triglycerides (TG) 
were determined by a Humalyzer Jnr. 18050 
chemistry analyzer (Human Diagnostica, Ger-
many) using commercial Fortress® test kits 
(Fortress Diagnostics Ltd., Antrim BT41 1QS, 
UK). Blood samples were collected in the 
morning after a 12 hr fast by venipuncture.  
Statistical analysis 
All data are expressed as mean ± S.D. Statisti-
cal differences between the levels of the indi-
vidual lipid indices among the three population 
sets were analysed through Student’s t-test or 
ANOVA where necessary and all p values < 
0.05 were considered significant. 
 
RESULTS 
The age, gender, and basal serum transaminases 
(AST and ALT) levels, as clinical features of 
the population as determined are summarized in 
Table 1. The healthy control volunteers en-
rolled in the study were considerably younger 
in comparison with the CHB-infected popu- 
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lation even though the mean age distribution 
among the categories of the population was 
found to be insignificant (p=0.3679). Table 1 
also shows significant overall male dominance 
compared to females among the categories of 
the population enrolled (p=0.0063) even 
though sampling was randomly done. As antici-
pated, there was a significant elevation of se-
rum transaminases (AST and ALT) levels 
among the chronic symptomatic CHB patients 
compared to the asymptomatic and healthy 
cohorts as shown in Table 1 (p= < 0.0001). 
The AST/ALT ratio among the healthy subjects 
was almost five to ten-fold less than those of 
the CHB-infected patients (p=0.0002).  
There was a significant decline in basal serum 
triglyceride levels (hypotriglycerideamia) 
among the CHB-infected cohorts compared to 
those of the healthy control (p=0.0010) as 
shown in Table 2. There was however no sig-
nificant variation in the serum triglyceride dis-
tribution among the CHB disease stages– 
chronic symptomatic and chronic asymptomatic 
– (p=0.3569). Measured serum total choles-
terol, HDL, and LDL levels did not differ sig-
nificantly among the categories of cohorts en-
rolled for investigation in the study (Table 2). 
No significant difference was observed in the 
coronary risk among the CHB- infected cohorts 
and the healthy control (p=0.1460). 
 Kwarteng et al. 
Table 1: Age, gender, and selected LFT parameters of volunteers enrolled in the study 
 













Age (years) 34.8 ± 12.49 33.0 ± 10.5 22.54 ± 1.90 0.3679 
Gender 
     Male(%) 















161.9 ± 18.10a 
  
12.3 ± 6.45a 
  






281.89 ± 16.40b 
  
29.21 ± 5.13b 
  






5.659 ± 1.12c 
  
2.591 ± 0.34c 
  
0.363 ± 0.08 
  
  0.0002c 
n=number of subjects 
a,b,c=significant at p≤0.05 











Total cholesterol (mmol/l)   5.19 ± 3.06 
                  
  5.38 ± 1.22 
                                    
  4.70 ± 0.71 
                                   
 0.6080 
                                  
Triglyceride (mmol/l) 0.76 ± 0.60a 1.12 ± 0.73a 1.69 ± 0.83 0.0010 
  
HDL (mmol/l) 
                                 
1.33 ± 0.69 
                                  
1.70 ± 0.54 
                                
1.92 ± 0.16 
                             
0.0970 
 
 LDL (mmol/l) 
                                    
4.83 ± 0.71 
                                
4.39 ± 1.01 
                             
3.98 ± 1.12 
                              
0.7470 
  
Coronary risk (HDL/LDL ratio) 
  
0.33 ± 0.17 
  
0.40 ± 0.17 
  
0.51 ± 0.15 
  
0.1460 
n = number of subjects ,aP > 0.05 













Dyslipidemia has been a recurrent finding from 
reports of most studies on metabolic complica-
tions associated with liver diseases. In one 
study, Bedimo et al. (2006) reported marked 
plasma lipid abnormalities associated with pa-
tients with HCV and HIV coinfection. In an-
other study, it was concluded that plasma levels 
of triglycerides, cholesterol, free fatty acids, 
HDL, LDL, apolipoproteins including - Apo A, 
and Apo B and the lipoprotein a (Lp(a)), were 
decreased in hepato-cellular carcinoma. It was 
suggested that this may be due to hepato-
cellular impairment and indicated poor progno-
sis (Jiang et al., 2006). Additionally, Mastoi et 
al. (2010) showed that serum total cholesterol 
levels (HDL-, LDL-cholesterol) were signifi-
cantly decreased in hepatitis B and C infected 
population compared to the control. Also, 
whereas serum triglyceride was significantly 
decreased in HCV-infected cohorts, it remained 
unchanged among HBV-infected population.    
 
The study reveals a marked gender disparity in 
the progression of the chronic hepatitis B infec-
tion among hosts despite the random sampling. 
This indicates that the virus interacts to differ-
ent extent with male and female genetic and 
physiological factors. Similar results have been 
observed in several studies of both human and 
transgenic mice populations with the latter 
showing a more overt and stronger gender bias 
in a ratio of 5-7:1 between male and female 
respectively as compared to humans (Yu and 
Chen., 1994; Wang et al., 2004; Yuen et al., 
2008). Proteomic and genomic studies have 
shown that the Hepatitis B X protein (HBXP), 
one of the important HBV antigens, potentiates 
androgen receptor activity by increasing signal 
activation of the receptors via phosphorylation 
(Chiu et al., 2007). In addition, viral antigen 
expression has been found to suppress apolipo-
protein A1 (Apo – A1) levels in vivo in males 
than in females according to one study using 
transgenic mice (Yang et al., 2010). The Apo-
A1 plays a critical role in immune resistance 
hence suppression of its expression indicates a 
compromised immunity and increased suscepti-
bility in host. This may account for the ob-
served male susceptibility to the chronic HBV 
disease progression among the studied CHB 
cohorts.  
 
There is an established fact that basal serum 
AST and ALT are of immense diagnostic value 
especially in evaluating suspected liver dys-
function (Sheth et al., 1998; Sorbi et al., 1999). 
These enzymes are compartmentalized in the 
hepatocytes where they play critical role in 
nitrogen recycling. Often, the rate of necrosis 
of the hepatocytes increases in liver diseases as 
with chronic hepatitis B infection through di-
verse molecular signalling and interaction. As 
the hepatocytes die, their intracellular enzymes 
such as transaminases (AST and ALT) leak into 
the extracellular matrix of the hepatic tissue 
and eventually diffuse into the blood circula-
tion. Due to the constant turn-over of worn-out 
hepatocytes in the body, there always exists 
some tolerable amount of these enzymes in the 
sera. The normal ranges of these enzymes are 
as follows: AST 2 – 35 IU/ml and ALT 2 – 
40IU/ml. Hence the instantaneous serum levels 
of the enzymes AST and ALT is predictive of 
the presence or absence of liver disease. Gener-
ally, elevated AST and ALT levels are sugges-
tive of mild to severe liver damage due to cir-
rhosis, hepatitis, alcoholism, and hepatocellular 
carcinoma. The greater extent of cirrhosis 
among the chronic symptomatic patients may 
account for their observed higher AST and 
ALT levels relative to those of the healthy con-
trol cohorts as recorded in Table 1. 
 
Whereas the serum levels of the enzymes AST 
and ALT are predictive of the presence or ab-
sence of liver disease, their ratio (AST/ALT) 
gives more insight into the functional integrity 
of the diseased liver. In one study reported by 
Sorbi et al. (1999), there was a profound over-
lap of AST/ALT ratio among steatohepatitis 
patients. During the study of the 140 patients 
with nonalcoholic steatohepatitis (NASH; con-
firmed by liver biopsy) or alcoholic liver dis-
ease, a mean AST/ALT ratio of 0.9 in patients 
with NASH and 2.6 in patients with alcoholic 
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liver disease was observed (ibid). Within the 
population studied, 87 percent of patients with 
an AST/ALT ratio of 1.3 or less had NASH (87 
percent sensitivity, 84 percent specificity). Al-
together, they found that AST/ALT ratio in-
creased with increased severity of the NASH as 
measured by the degree of fibrosis. A mean 
ratio of 1.4 was found in patients with cirrhosis 
related to NASH. These varying ratios further 
reinforce their potential clinical utility at help-
ing in classifying various forms of liver dis-
eases pertaining to steatohepatitis and alcoholic 
liver disease (ibid). 
 
This study showed averagely higher AST/ALT 
ratio among the CHB-infected population com-
pared to the healthy control perhaps due in part 
to mild to significant hepatic cirrhosis among 
the CHB-infected cohorts. As expected, the 
average AST/ALT ratio of the chronic sympto-
matic patients diagnosed with severe cirrhosis 
was twice (5.659) as higher as that for the as-
ymptomatic patients (2.591) diagnosed with 
minor cirrhosis. Several studies have also 
shown that AST/ALT ratio increases above 1 in 
most cases of chronic liver diseases including 
chronic active hepatitis B (McClatchey, 2002). 
It is suggested that, irrespective of the aetiol-
ogy, the AST/ALT ratio increases above 1 in 
cases of liver cirrhosis (William and Hoofna-
gle, 1988; Mastoi et al., 2010).  Even though 
the reason for this observation is unknown, it 
has been suggested that sinusoidal clearance of 
serum AST decreases in progressive cirrhosis 
condition leaving the basal AST levels far in 
excess of the ALT (Nyblom et al., 2004; Ny-
blom et al., 2006; Park et al., 2000; Alempi-
jevic et al., 2009). In end-stage liver disease, 
the enzyme levels fall to normal or subnormal 
levels as functional hepatocytes become de-
pleted due to progressive necroinflammation in 
the damaged liver. Hence, in most end-stage 
liver diseases, AST/ALT ratio is 1. These find-
ings confirm the usefulness of the ratio as an 
adjunct index for monitoring extent of cirrhosis 
among the CHB-infected population prior to 
the terminal stage of the disease where there is 
permanent liver decompensation. 
The results from Table 2 is consistent with the 
reported works of Ianello et al. (2003) and Luo 
et al. (2007) who showed an inverse correlation 
between HBV-infection and elevated serum 
triglyceride levels even though their studies 
were carried out in different geographical loca-
tions and settings. Upon infection, the viral X 
protein (HBxP) interacts with host hepatic 
metabolic genes such as sterol regulator ele-
ment binding protein-1 (SREBP-1), carbohy-
drate regulator element binding protein 
(ChREBP), peroxisome proliferator activator 
receptor-gamma (PPAR-γ), among others.  
 
The consequence of this interaction is to switch 
hepatic metabolism from fatty acid synthesis 
and secretion via lipoproteins to increased he-
patic lipid synthesis and storage (Shlomai and 
Shaul, 2009; Kim et al., 2007). Thus the liver 
becomes more adipogenic sequestering most of 
the lipids that diffuse into it. This scenario cre-
ates a steatotic condition in the infected liver as 
have been reported by some researchers 
(Altiparmak et al. 2005; Thormopuolos et al., 
2006; Tsochatzis et al. 2007; and Cindoruk et 
al., 2007). This may account in part for the 
observed decreased circulating triglyceride in 
serum of the hepatitis B infected population in 
relation to the healthy control. Even though the 
liver is thought of as the central player in regu-
lation of lipid metabolism, it must be empha-
sized that the liver does so through effective 
coordination with other auxiliary organs and 
tissues from the body by means of chemical 
messengers in the form of cytokines and steroid 
hormones. These exocrine and endocrine mes-
sengers may modulate, potentiate, or synergize 
to varying extent with the homoeostatic func-
tions of the HBV infected liver in controlling 
circulating lipid levels in sera of hosts.  Hence, 
dysregulation of these factors due to the 
chronic HBV infection can partly be implicated 
for the observed distortions in the serum lipid 
distribution. This may account for the margin-
ally lower triglyceride levels among the chronic 
symptomatic patients even though not statisti-
cally significant (p=0.3569). 
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The prolonged surge in proinflammatory cytok-  
ines such as TNF-alpha, IL-1, IL-6, IFN-α, etc. 
observed following the chronic state of the 
HBV-infection (Argiles et al., 1985; Grunfeld 
et al., 1991; Naeem et al., 2001; Khovidhunkit 
et al., 2004) could have contributed to the ob-
served distortions in the various lipid indices of 
the hepatitis B-infected population. Cytokines 
such as the TNF-α, IL-1, IL-6, IFN-α, etc. have 
been reported to increase lipogenesis, decrease 
clearance of circulating LDLs, and inhibit he-
patic lipase activity (Feingold et al., 1992; 
Feingold and Grunfeld, 1987; Feingold et al., 
1989; Nonogaki et al., 1995). This probably 
accounts for the observed slight increase in the 
serum LDL levels among the HBV-infected 
populations as shown in Table 2. The decreased 
HDL levels may be due to the decrease in Apo-
A1 secretion in the hepatitis B-infected patients 
with cirrhosis (Lee et al., 2010). Total serum 
cholesterol is largely based on the cholesterol 
contents of HDL and LDLs. The observed 
slight increase in cholesterol among the chronic 
hepatitis B-infected cohorts from Table 2 might 
be due to the contribution by the LDL fraction.  
 
CONCLUSION 
In conclusion, significant hypotriglycerideamia 
occurs among chronic hepatitis B-infected pa-
tients in Kumasi, Ghana. Even though there is 
enough literature to account for the mechanism 
of decreased serum triglyceride levels in 
chronic hepatitis B-infected hosts, the essence 
of this phenomenon whether as a viral survival 
strategy or mere pathological consequence re-
mains to be established. 
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